NF-κB activation, dependent on acetylation/deacetylation, contributes to HIF-1 activity and migration of bone metastatic breast carcinoma cells

Molecular Cancer Research

Volumn 7, Issue 8, 2009, Pages 1328-1341

  Bendinelli, Paola ^a   Matteucci, Emanuela ^a   Maroni, Paola ^b   Desiderio, Maria Alfonsina ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; NERVE CELL ADHESION MOLECULE; PROTEIN P50; PROTEIN TYROSINE KINASE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN; DNA; HISTONE DEACETYLASE 3; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PROTEIN C JUN; PROTEIN KINASE P60; TUMOR MARKER;

ACETYLATION; ANIMAL CELL; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER CELL; CELL CLONE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STIMULATION; CONTROLLED STUDY; DEACETYLATION; ENZYME ACTIVATION; EPIGENETICS; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MESENCHYME CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; WILD TYPE; ANIMAL; BONE TUMOR; BREAST TUMOR; CANCER INVASION; CELL MOTION; DISEASE MODEL; FEMALE; GENE SILENCING; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ACETYLATION; ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; I-KAPPA B PROTEINS; MICE; NEOPLASM INVASIVENESS; NF-KAPPA B; PHENOTYPE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS PP60(C-SRC); SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 69449107156     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0548     Document Type: Article

References (63)

1. Weigelt B, Peterse JL, van't Veer JL. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005;5:591-602.
2. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell 2006; 127:679-695
3. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-549 (Pubitemid 36808649)
4. Garcia T, Jackson A, Bachelier R, et al. A convenient clinically relevant model of human breast cancer bone metastasis. Clin Exp Metastasis 2008;25:33-42. (Pubitemid 351191224)
5. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-436 (Pubitemid 44050137)
6. Huber MA, Azoitei N, Baumann B, et al. NF-κB is essential for epithelialmesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004;114:569-581 (Pubitemid 39572107)
7. Park BK, Zhang H, Zeng Q, et al. NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007;13:62-69 (Pubitemid 46067387)
8. Anguilera C, Fernández-Majada V, Inglés-Esteve J, Rodilla V, Bigas A, Espinosa L. Efficient nuclear export of p65-IκBα complexes requires 14-3-3 proteins. J Cell Sci 2006;119:3695-3704 (Pubitemid 44501873)
9. Chen L-F, Greene WC. Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol 2004;5:392-401.
10. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007;8:49-62. (Pubitemid 46012014)
11. Min C, Eddy SF, Sherr DH, Sonenshein GE. NF-κB and epithelial to mesenchymal transition of cancer. J Cell Biochem 2008;104:733-744 (Pubitemid 351830825)
12. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as prerequisite for carcinoma invasion and metastasis. Cancer Res 2006;66:8319-8326 (Pubitemid 44449137)
13. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68-72.
14. Maroni P, Bendinelli P, Matteucci E, Desiderio MA. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-κB. Carcinogenesis 2007;28:267-279 (Pubitemid 46321842)
15. B receptors regulates the abundance of ET-1 mRNA in vascular endothelial cells. Br J Pharmacol 2008;153:1420-1431
16. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 2006;4:601-605 (Pubitemid 44497213)
17. Milani M, Harris AL. Targeting tumour hypoxia in breast cancer. Eur J Cancer 2008;44:2766-2773
18. Semenza GL. HIF-1 andtumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-67.
19. Jung Y-J, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003;17:2115-2117
20. Desiderio MA. Hepatocyte growth factor in invasive growth of carcinomas. Cell Mol Life Sci 2007;64:1341-1354 (Pubitemid 46889234)
21. Tacchini L, De Ponti C, Matteucci E, Follis R, Desiderio MA. Hepatocyte growth factor activated NF-κB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis 2004;25:2089-2100 (Pubitemid 39534845)
22. Calvani M, Trisciuoglio D, Bergamaschi CC, Shoemaker RH, Melillo G. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res 2008;68:285-291
23. Haddad JJ, Harb HL. Cytokines and the regulation of hypoxia-inducible factor (HIF)1α. Int Immunopharmacol 2005;5:461-483 (Pubitemid 40430755)
24. Görlach A, Bonello S. The cross-talk between NF-κB and HIF-1: further evidence for a significant liaison. Biochem J 2008;412:e17-9.
25. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-939 (Pubitemid 38798858)
26. Yang M-H, Wu M-Z, Chiou S-H, et al. Direct regulation of TWIST by HIF-1α promotes metastasis. Nat Cell Biol 2008;10:295-305.
27. Lee Y-H, Albig AR, Regner MA, Schiemann BJ, Schiemann WP. Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-β in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis 2008;29:2243-2251
28. Ducasse M, Brown MA. Epigenetic aberrations and cancer. Mol Cancer 2006;5:60-70.
29. Yeatman TJ. A renaissance for Src. Nat Rev Cancer 2004;4:470-480
30. Huang WC, Chen JJ, Inoue H, Chen CC. Tyrosine phosphorylation of I-κ B kinase α/β by protein kinase C-dependent c-Src activation is involved in TNF-α-induced cyclooxygenase-2 expression. J Immunol 2003;170:4767-4775 (Pubitemid 36519986)
31. Matteucci E, Ridolfi E, Maroni P, Bendinelli P, Desiderio MA. c-Src/histone deacetylase 3 interaction is crucial for hepatocyte growth factor-dependent decrease of CXCR4 expression in highly invasive breast tumor cells. Mol Cancer Res 2007;5:833-845 (Pubitemid 47294811)
32. Gao Z, He Q, Peng B, et al. Regulation of nuclear translocation of HDAC3 by IκBα is required for tumor necrosis factor inhibition of peroxisome proliferator-activated receptor γ function. J Biol Chem 2006;281:4540-4547 (Pubitemid 43847886)
33. Jiao X, Katiyar S, Liu M, et al. Disruption of c-Jun reduces cellular migration and invasion through inhibition of c-Src and hyperactivation of ROCK II kinase. Mol Cell Biol 2008;19:1378-1390 (Pubitemid 351805093)
34. Gao Z, Chiao P, Zhang X, et al. Coactivators and corepressors of NF-κB in IκBα gene promoter. J Biol Chem 2005;280:21091-21098 (Pubitemid 40805668)
35. Kasper LH, Brindle PK. Mammalian gene expression program resiliency: the roles of multiple coactivator mechanisms in hypoxia-responsive transcription. Cell Cycle 2006;5:142-146
36. Wolf K, Mazo I, Leung H, et al. Compensation mechanism in tumor call migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003;160:267-277 (Pubitemid 36254960)
37. Perkins ND. The Rel/NF-κB family: friend and foe. Trends Biochem Sci 2000;25:434-440
38. Matteucci E, Locati M, Desiderio MA. Hepatocyte growth factor enhances CXCR4 expression favouring breast cancer cell invasiveness. Exp Cell Res 2005;310:176-185 (Pubitemid 41393698)
39. Hu J, Colburn NH. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kB/p65 DNA binding. Mol Cancer Res 2005;3:100-109 (Pubitemid 40271140)
40. Kiernan R, Brès V, Ng RW, et al. Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003;278:2758-2766 (Pubitemid 36801357)
41. Dejardin E, Bonizzi G, Bellahcène A, Castronovo V, Merville MP, Bours V. Highly-expressed p100/p52 (NFκB2) sequesters other NF-κ-B-related proteins in the cytoplasm of human breast cancer cells. Oncogene 1995;11:1835-1841.
42. Kvietikova I, Wenger RH, Marti HH, Gassmann M. The transcription factors ATF-1 and CREB-1 bind constitutively to hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acid Res 1995;23:4542-4550 (Pubitemid 126003251)
43. Agani F, Semenza GL. Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity. Mol Pharmacol 1998;4:749-754 (Pubitemid 28523166)
44. Alfranca A, Gutiérrez MD, Vara A, Aragonés J, Vidal F, Landázuri MO. c-Jun and hypoxia-inducible factor 1 functionally cooperate in hypoxia-induced gene transcription. Mol Cell Biol 2002;22:12-22. (Pubitemid 33144252)
45. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A 1994;91:609-613 (Pubitemid 24041451)
46. Manna PR, Stocco DM. Crosstalk of CREB and Fos/Jun on a single cis-element: transcriptional repression of the steroidogenic acute regulatory protein gene. J Mol Endocrinol 2007;39:261-277
47. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005;65:967-971 (Pubitemid 40216458)
48. Firulli AB, Conway SJ. Phosphoregulation of Twist1 provides a mechanism of cell fate control. Curr Med Chem 2008;15:2641-2647
49. Matteucci E, Ridolfi E, Desiderio MA. Hepatocyte growth factor differently influences Met-E-cadherin phosphorylation and downstream signaling pathway in two models of breast cells. Cell Mol Life Sci 2006;63:2016-2026 (Pubitemid 44359742)
50. Senese S, Zaragoza K, Minardi S, et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007;27:4784-4795 (Pubitemid 47016131)
51. Lou Y, Preobrazhenska O, auf dem Keller U, et al. Epithelial-mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis. Dev Dyn 2008;237:2755-2768
52. Sun H-L, Liu Y-N, Huang Y-T, et al. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-κB signaling to HIF-1α accumulation during hypoxia. Oncogene 2007;26:3941-3951
53. Kingsley LA, Fournier PGJ, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007;6:2609-2617
54. Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer 2003;2:1-21.
55. Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U SA 2008;105:14867-14872
56. Gao CF, Xie Q, Su YL, et al. Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci U S A 2005;102:10528-10533 (Pubitemid 41061588)
57. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiroaka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007;67:4157-4163 (Pubitemid 46815061)
58. Shim H, Lau SK, Devi S, Yoon Y, Cho HT, Liang Z. Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1α. Biochem Biophys Res Comm 2006;346:252-258 (Pubitemid 43865990)
59. Wilson CL, Thomsen J, Hoivik DJ, et al. Aryl hydrocarbon (Ah) nonresponsiveness in estrogen receptor-negative MDA-MB231 cells is associated with expression of variant Arnt protein. Arch Biochem Biophys 1997;346:65-73. (Pubitemid 27415296)
60. Neil JR, Schiemann WP. Altered TAB1:IκB kinase interaction promotes transforming growth factor β-mediated nuclear factor-κB activation during breast cancer progression. Cancer Res 2008;68:1462-1470 (Pubitemid 351346854)
61. Tacchini L, Matteucci E, De Ponti C, Desiderio MA. Hepatocyte growth factor signaling regulates transactivation of genes belonging to the plasminogen activation system via hypoxia inducible factor-1. Exp Cell Res 2003;290:391-401. (Pubitemid 37272181)
62. Kostyniuk CL, Dehm SM, Batten D, Bonham K. The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases. Oncogene 2002;21:6340-6347
63. Ridolfi E, Matteucci E, Maroni P, Desiderio MA. Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs. Br J Cancer 2008;99:1623-1634